LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of ...
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Savara, with a price target of $16.00. Rahimi covers the Healthcare sector, focusing on stocks such as ...
Savara Inc. (Nasdaq: SVRA) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote bar is ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 10, 2026, the ...
Savara Inc. Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare ...
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024. Savara said it had enough cash to fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results